Fondaparinux em intervenção coronária percutânea no tratamento da síndrome coronária aguda

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorde Andrade, Pedro Beraldo
dc.creatorTebet, Marden André
dc.creatorNogueira, Ederlon Ferreira
dc.creatorde Andrade, Mônica Vieira Athanazio
dc.creatorBarbosa, Robson Alves
dc.creatorLabrunie, André
dc.creatorMattos, Luiz Alberto
dc.date2014-05-27T11:26:31Z
dc.date2016-10-25T18:37:19Z
dc.date2014-05-27T11:26:31Z
dc.date2016-10-25T18:37:19Z
dc.date2012-06-01
dc.date.accessioned2017-04-06T01:58:56Z
dc.date.available2017-04-06T01:58:56Z
dc.identifierRevista Brasileira de Cardiologia Invasiva, v. 20, n. 2, 2012.
dc.identifier0104-1843
dc.identifierhttp://hdl.handle.net/11449/73352
dc.identifierhttp://acervodigital.unesp.br/handle/11449/73352
dc.identifier10.1590/S2179-83972012000200008
dc.identifierS2179-83972012000200008
dc.identifier2-s2.0-84863737692.pdf
dc.identifier2-s2.0-84863737692
dc.identifierhttp://dx.doi.org/10.1590/S2179-83972012000200008
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/894161
dc.descriptionBackground: Fondaparinux is considered an agent with a well-established safety and efficacy profile in the treatment of non-ST segment elevation acute coronary syndromes, but when used alone, is associated to a higher incidence of thrombotic complications during invasive coronary procedures, requiring the supplementation of an anti-IIa agent. This study aimed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) in patients with non-ST segment elevation acute coronary syndromes previously treated with fondaparinux. Methods: Prospective, controlled registry enrolling 127 consecutive patients submitted to an early invasive stratification during treatment with fondaparinux, with supplementation of intravenous unfractionated heparin at a dose of 85 U/kg at the time of PCI. Results: The rate of the composite primary endpoint including death, acute myocardial infarction, stroke, stent thrombosis or emergency myocardial revascularization was 3.2%. The cumulative incidence of major bleeding and vascular complications was 3.2%. There were no cases of guidecatheter thrombosis or abrupt vessel closure. Conclusions: PCI in patients with acute coronary syndromes receiving fondaparinux is associated with a low rate of major adverse cardiovascular ischemic events and severe hemorrhagic complications. Supplementation of unfractionated heparin during the invasive procedures eliminates the risk of catheter-related thrombosis.
dc.languageeng
dc.languagepor
dc.relationRevista Brasileira de Cardiologia Invasiva
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute coronary syndrome
dc.subjectAngioplasty
dc.subjectAnticoagulants
dc.subjectFondaparinux
dc.subjectStents
dc.subjectfondaparinux
dc.subjectheparin
dc.subjectacute coronary syndrome
dc.subjectacute heart infarction
dc.subjectbleeding
dc.subjectcatheter thrombosis
dc.subjectclinical trial
dc.subjectdeath
dc.subjectdisease association
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectemergency care
dc.subjectheart muscle ischemia
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectnon st segment elevation acute coronary syndrome
dc.subjectpercutaneous coronary intervention
dc.subjectprospective study
dc.subjectrevascularization
dc.subjectstent thrombosis
dc.subjectstroke
dc.subjectvascular disease
dc.titleFondaparinux em intervenção coronária percutânea no tratamento da síndrome coronária aguda
dc.typeOtro


Este ítem pertenece a la siguiente institución